Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
10.34
Nov 17 • 3:59 PM ET Dollar change-1.43 Percentage change(-12.15%)
Aftermarket Close
10.34
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Nov 16, 8:15 AMJasper Therapeutics completes first-cohort enrollment in Phase 2 vensobafusp alfa renal basket study
Index
-
Market Cap
11.46M
Enterprise Value
142.53M
Income
-157.49M
Sales
8.00M
Book/sh
-126.45
Cash/sh
122.45
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
22
IPO
Jan 10, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
1.43
P/B
-
P/C
0.08
P/FCF
-
EV/EBITDA
-
EV/Sales
17.82
Quick Ratio
10.59
Current Ratio
10.59
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-147.98
EPS next Y
-15.51
EPS next Q
-8.11
EPS this Y
82.56%
EPS next Y
24.92%
EPS next 5Y
48.97%
EPS past 3/5Y
27.39% 48.97%
Sales past 3/5Y
- -
EPS Y/Y TTM
16.44%
Sales Y/Y TTM
-
EPS Q/Q
-297.61%
Sales Q/Q
-
Insider Own
-
Insider Trans
-
Inst Own
42.65%
Inst Trans
-
ROA
-153.74%
ROE
-255.05%
ROIC
-124.48%
Gross Margin
-4.28%
Oper. Margin
-591.40%
Profit Margin
-1968.62%
SMA20
-29.83%
SMA50
-36.87%
SMA200
-56.24%
Trades
Shs Outstand
1.11M
Shs Float
-
52W High
72.60 -85.76%
52W Low
9.45 9.38%
Volatility
14.50% 12.79%
ATR (14)
1.99
RSI (14)
30.38
Beta
3.34
Rel Volume
2.66
Avg Volume
18.43K
Volume
49,038
Perf Week
-29.90%
Perf Month
-27.80%
Perf Quarter
-53.84%
Perf Half Y
-57.88%
Perf YTD
-81.17%
Perf Year
-80.74%
Perf 3Y
-94.52%
Perf 5Y
-99.60%
Perf 10Y
-
Prev Close
11.77
Price
10.34
Change %
-12.15%
Consensus
Strong Buy
Avg. Price Target
$264.67
Implied Upside
+2,459.7%
Analysts14incl. previous ratings
Rating Distribution9 Buy · 5 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 14, 2026Resumed
WWilliam Blair
Outperform
Aug 12, 2026Initiated
PPiper Sandler
Overweight$2-80.7%
May 15, 2026Downgrade
TD logoTTD Cowen
Buy → Hold
Mar 23, 2026Resumed
UBS logoUUBS
Neutral$1.50-85.5%
Jan 13, 2026Initiated
RRodman & Renshaw
Buy$17+64.4%
Jul 08, 2025Downgrade
RY logoRRBC Capital Mkts
Outperform → Sector Perform$5-51.6%
Jul 08, 2025Downgrade
BMO logoBBMO Capital Markets
Outperform → Market Perform$4-61.3%
Jul 07, 2025Downgrade
WWilliam Blair
Outperform → Mkt Perform
Jul 07, 2025Downgrade
CCantor Fitzgerald
Overweight → Neutral
Feb 13, 2025Initiated
UBS logoUUBS
Buy$38+267.5%
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
PresidentMr. Jeetinder Singh Mahal M.B.A.
COO & Interim Corporate SecretaryMr. Matthew E. Ros
Senior Vice President of Human ResourcesMr. Matthew Ford
Senior Vice President of Regulatory AffairsDr. Lisa Pitt Pharm.D.
Ph.D.Dr. Wenru Song M.D.